US · GELS
Gelteq Limited Ordinary Shares
- Sector
- Healthcare · Drug Manufacturers - Specialty & Generic
- Headquarters
- Caulfield, VIC 3162
- Website
- gelteq.com
Price · as of 2025-06-30
$0.66
Market cap 6.95M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | $1.79 | +172.08% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | |||||
| 2021 | |||||
| 2022 | |||||
| 2023 | $0.10 | $8.70 | |||
| 2024 | |||||
| 2025 | $1.56 | $0.00 |
AI valuation
Our deep-learning model estimates Gelteq Limited Ordinary Shares's (GELS) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $0.66
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$1.79
+172.08% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| GELS | Gelteq Limited Ordinary S… | $0.66 | 6.95M | — | +172% | — | — | — | — | — | — | — | — | 100.00% | -3317.65% | -4011.86% | 0.00% | -28.47% | 0.00% | 0.27 | -2.90 | 0.27 | 0.14 | -1.10 | — | — | 40580.00% | — | -0.98 | -31.93% | — | — | — | — | — | — | — |
| AYTU | Aytu BioPharma, Inc. | $2.57 | 20.82M | +791% | +627% | — | — | -1.04 | 0.74 | 0.21 | -1.31 | — | -0.61 | 69.04% | -11.79% | -20.43% | -58.10% | -44.62% | -11.16% | 1.21 | -2.11 | 1.26 | 0.98 | 1.72 | -2448.00% | 184.00% | 20082.00% | -36.55% | -0.03 | -29.45% | 0.00% | 0.00% | 31.33% | -0.78 | -1.18 | 0.09 | -3.20 |
| BFRG | Bullfrog AI Holdings, Inc… | $0.58 | 5.64M | +5,971% | — | — | — | -2.12 | 2.99 | — | -1.35 | — | 2.99 | 0.00% | — | — | -185.12% | 2867.39% | -167.95% | 0.00 | -398.52 | 9.43 | 9.24 | 0.78 | -449.00% | -10000.00% | -652.00% | -37.80% | -9.54 | 2223.04% | 0.00% | 0.00% | 18.94% | -1.30 | -1.68 | — | 7.68 |
| BFRI | Biofrontera Inc. | $0.91 | 10.62M | +16,739% | -59% | — | — | -0.29 | 1.14 | 0.14 | -0.28 | — | 1.15 | 50.12% | -46.14% | -47.61% | -384.98% | -281.81% | -70.99% | 1.11 | -8.17 | 1.72 | 0.93 | 0.07 | -7527.00% | 949.00% | -5851.00% | -203.55% | -0.85 | -169.15% | 0.00% | 0.00% | 99.29% | -0.24 | -0.40 | 0.11 | -7.68 |
| BGLC | BioNexus Gene Lab Corp. | $2.72 | 4.89M | +1,907% | +316% | -93% | — | -4.11 | 0.79 | 0.69 | -1.70 | — | 0.79 | 13.56% | -16.55% | -16.81% | -17.78% | -39.19% | -14.64% | 0.03 | -74.42 | 3.81 | 3.05 | 2.93 | -4118.00% | -266.00% | 2885.00% | -37.43% | -1.15 | -61.29% | 0.00% | 0.00% | 0.00% | -1.53 | -0.98 | 0.25 | 2.45 |
| COCP | Cocrystal Pharma, Inc. | $1.05 | 10.76M | — | — | — | — | -0.99 | 1.82 | — | -0.52 | 0.00 | 1.82 | 0.00% | — | — | -97.50% | -1066.39% | -78.29% | 0.19 | — | 4.77 | 4.56 | 0.45 | 9042632.00% | — | 1156.00% | -95.36% | -6.79 | -983.78% | 0.00% | 0.00% | 0.00% | -0.52 | -0.56 | — | -35.62 |
| EVGN | Evogene Ltd. | $0.88 | 7.65M | +2,548% | -33% | — | — | -0.47 | -5.81 | 0.99 | -0.39 | — | -0.62 | 39.81% | -255.36% | -193.69% | -340.58% | 381.57% | -39.69% | -8.87 | -175.27 | 1.15 | 0.90 | 0.16 | -4474.00% | 5090.00% | -910.00% | -241.06% | -1.05 | 356.85% | 0.00% | 0.00% | 0.00% | -0.28 | -0.29 | 0.70 | -10.92 |
| IMNN | Imunon, Inc. | $3.25 | 8.19M | — | — | — | — | -0.56 | 2.47 | — | -0.32 | — | 2.47 | 0.00% | — | — | -211.21% | 3263.61% | -117.72% | 0.27 | — | 1.67 | 1.23 | 0.26 | -2500.00% | — | -303.00% | -180.33% | -3.94 | 3221.31% | 0.00% | 0.00% | 4.96% | -0.30 | -0.30 | — | -63.56 |
| IMRN | Immuron Limited | $0.77 | 4.96M | +2,352% | +18,330% | — | — | -3.14 | 2.04 | 2.25 | -2.00 | — | 2.04 | 65.39% | -73.34% | -71.58% | -50.30% | -304.73% | -40.68% | 0.01 | -731.63 | 5.07 | 3.39 | 0.51 | -2623.00% | 4863.00% | 436.00% | -37.47% | -3.12 | -349.90% | 0.00% | 0.00% | 0.00% | -1.99 | -1.73 | 1.46 | -6.75 |
| PRPH | ProPhase Labs, Inc. | $0.15 | 710.55K | +15,560% | +1,020% | — | +135,988% | -1.62 | 10.90 | 11.84 | -3.22 | -0.97 | -10.50 | -2.22% | -570.59% | -788.24% | -174.58% | -79.42% | -63.85% | 3.34 | -11.53 | 0.95 | 0.65 | -0.74 | 16633.00% | -8475.00% | 2717.00% | -23.02% | -0.55 | -37.92% | 0.00% | 0.00% | 0.00% | -2.69 | -5.64 | 15.37 | -2.37 |
| SBFM | Sunshine Biopharma, Inc. | $1.20 | 5.89M | +4,340% | +64,945,046% | — | — | -0.33 | 0.07 | 0.05 | 1.37 | — | 0.08 | 30.60% | -16.67% | -14.72% | -22.97% | -54.65% | -17.73% | 0.04 | -662.41 | 4.11 | 2.15 | 1.69 | -9792.00% | 4475.00% | 5530.00% | -885.54% | -1.98 | -146.04% | 0.00% | 0.00% | 187.20% | 1.21 | 0.48 | -0.20 | -1.74 |
About Gelteq Limited Ordinary Shares
Gelteq Limited focuses on developing and commercializing a gel-based delivery system for humans and animals. It offers white label gel-based delivery solutions for prescription drugs, over-the-counter products, nutraceuticals and sports, pet care, and other products. The company was incorporated in 2017 and is headquartered in Caulfield, Australia.
- CEO
- Nathan Jacob Givoni
- Employees
- 7
- Beta
- -0.32
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($1.79 ÷ $0.66) − 1 = +172.08% (DCF, example).